- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1,087)
9 result(s) found for: Azole.
Displaying page 1 of 1.
| EudraCT Number: 2017-001290-17 | Sponsor Protocol Number: F901318/0032 | Start Date*: 2018-03-30 |
| Sponsor Name:F2G Biotech GmbH (FN 483749 x) | ||
| Full Title: An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in pat... | ||
| Medical condition: invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) ES (Ongoing) NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000386-32 | Sponsor Protocol Number: F901318/0041 | Start Date*: 2022-01-21 | |||||||||||
| Sponsor Name:F2G Ltd. | |||||||||||||
| Full Title: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with... | |||||||||||||
| Medical condition: invasive fungal infections due to Aspergillus spp. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000627-40 | Sponsor Protocol Number: IA-DUET | Start Date*: 2020-12-28 | |||||||||||
| Sponsor Name:Erasmus MC | |||||||||||||
| Full Title: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET) | |||||||||||||
| Medical condition: Invasive aspergillosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005799-41 | Sponsor Protocol Number: LOC/11-17-ATCF | Start Date*: 2012-10-04 | ||||||||||||||||
| Sponsor Name:CHU de Rennes (Rennes University Hospital Centre) | ||||||||||||||||||
| Full Title: Azole Therapy in Cystic Fibrosis (ATCF) : Efficacy of itraconazole and of voriconazole in patients with cystic fibrosis and presenting with persistent positive sputums for Aspergillus | ||||||||||||||||||
| Medical condition: Cystic fibrosis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2004-001341-14 | Sponsor Protocol Number: BAY 59-7939 / 11527 | Start Date*: 2004-11-04 | |||||||||||
| Sponsor Name:Bayer HealthCare AG | |||||||||||||
| Full Title: Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXaHIP-OD Study | |||||||||||||
| Medical condition: Deep Venous Thrombosis prophylaxis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) SE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002565-18 | Sponsor Protocol Number: SCY-078-206 | Start Date*: 2019-10-04 | |||||||||||
| Sponsor Name:SCYNEXIS, Inc. | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 with Voriconazole in Patients with Invasive Pulmonary Aspergillosis (SCYNERGIA) | |||||||||||||
| Medical condition: Patients with Invasive Pulmonary Aspergillosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-003868-59 | Sponsor Protocol Number: WSA-CS-004 | Start Date*: 2011-05-12 | |||||||||||
| Sponsor Name:Astellas Global Pharma Development, Inc. | |||||||||||||
| Full Title: A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Apsergillus species or other fi... | |||||||||||||
| Medical condition: Invasive fungal disease caused by Aspergillus species or other filamentous fungi. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed) CZ (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005106-25 | Sponsor Protocol Number: D8241C00001 | Start Date*: 2021-11-15 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced... | |||||||||||||
| Medical condition: Advanced Haematological Malignancies | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003951-18 | Sponsor Protocol Number: WSA-CS-008 | Start Date*: 2007-05-29 | |||||||||||
| Sponsor Name:Astellas Global Pharma Development, Inc. | |||||||||||||
| Full Title: A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus a Caspofungin followed by Voriconazole regimen in the treatment of candidemia and other invasive Ca... | |||||||||||||
| Medical condition: Treatment of Candidemia and other invasive Candida infections | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.